Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer

Videos — January 10, 2018

Featuring:

Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.

Related Articles